

Oncology Nursing Society *Chemotherapy and Immunotherapy Guidelines
and Recommendations for Practice*

Errata

The following corrections have been made in the second and subsequent printings as well as in the e-book:

page 211, second column, second line, sentence changed to read “When administering vesicants via a peripheral IV site, limit the infusion time to ≤ 30 minutes and remain with the patient during the entire infusion.”

page 304, Table 15-4, the following drugs should be listed under the classification “5-HT₃ antagonist”:

- Granisetron
- Granisetron transdermal
- Ondansetron
- Palonosetron